All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub
Brought to you by Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Abbvie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more
View on  

Important announcement

🚨NEWS🚨

Singapore’s HSA approves belantamab mafodotin combinations for relapsed/refractory #MultipleMyeloma, with BVd in patients with ≥1 prior therapy and BPd in those with ≥1 prior therapy including lenalidomide, based on data from the phase III DREAMM-7 and DREAMM-8 trials, respectively.

Read more: https://multiplemyelomahub.com/medical-information/singapores-hsa-approves-belantamab-mafodotin-combinations-for-rrmm
View all drug updates

More drug updates

VIEW ALL
Important announcement
China’s NMPA approves felzartamab, an anti-CD38 mAb for injection, in combination with lenalidomide and dexamethasone for the treatment of patients with #MultipleMyeloma and ≥1 prior line of therapy. Read more: https://chinadaily.com.cn/a/202608/14/WS6a7ee441a31073853ec53602.html
Aug 19, 2026
Important announcement
@FDA grants accelerated approval to iberdomide, an oral CELMoD, in combination with daratumumab + dexamethasone (IberDd), for the treatment of patients with RRMM and ≥1 prior line of therapy, including a PI and an IMiD. Read more: https://multiplemyelomahub.com/medical-information/fda-approves-iberdomide-dd-for-rrmm
Aug 17, 2026
Important announcement
@Saudi_FDA approves iberdomide, an oral CELMoD, in combination with daratumumab + dexamethasone for the treatment of RRMM, marking the first regulatory approval globally for a CELMoD in #MultipleMyeloma. Read more: https://multiplemyelomahub.com/medical-information/sfda-grants-first-global-approval-of-iberdomide-for-rrmm
Aug 13, 2026
Important announcement
@US_FDA accepts new drug application for mezigdomide, an oral CELMoD, in combination with carfilzomib + dexamethasone for the treatment of RRMM based on results from the phase III SUCCESSOR-2 trial. Read more: https://bit.ly/4gCBfrJ
Jul 16, 2026